Duality Advisers LP Grows Stake in Medpace Holdings, Inc. (NASDAQ:MEDP)

Duality Advisers LP lifted its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 682.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 6,613 shares of the company's stock after buying an additional 5,768 shares during the period. Duality Advisers LP's holdings in Medpace were worth $2,027,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Portside Wealth Group LLC boosted its stake in shares of Medpace by 14.8% during the 4th quarter. Portside Wealth Group LLC now owns 1,419 shares of the company's stock worth $435,000 after buying an additional 183 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in shares of Medpace by 355.2% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,555 shares of the company's stock worth $1,090,000 after buying an additional 2,774 shares during the last quarter. Louisiana State Employees Retirement System acquired a new position in shares of Medpace during the 4th quarter worth about $1,992,000. Chase Investment Counsel Corp lifted its stake in Medpace by 3.2% in the 3rd quarter. Chase Investment Counsel Corp now owns 9,849 shares of the company's stock valued at $2,384,000 after purchasing an additional 301 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its stake in Medpace by 42.7% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 19,920 shares of the company's stock valued at $4,823,000 after purchasing an additional 5,956 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Medpace news, VP Susan E. Burwig sold 102 shares of the firm's stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $403.00, for a total transaction of $41,106.00. Following the completion of the sale, the vice president now directly owns 15,181 shares in the company, valued at $6,117,943. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, VP Susan E. Burwig sold 102 shares of the firm's stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $403.00, for a total transaction of $41,106.00. Following the transaction, the vice president now directly owns 15,181 shares of the company's stock, valued at $6,117,943. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Medpace Investors, Llc sold 50,000 shares of the firm's stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $391.75, for a total transaction of $19,587,500.00. Following the transaction, the insider now directly owns 5,539,947 shares in the company, valued at $2,170,274,237.25. The disclosure for this sale can be found here. Insiders sold 189,340 shares of company stock worth $76,651,647 over the last three months. Insiders own 20.30% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on MEDP. Jefferies Financial Group upgraded shares of Medpace from a "hold" rating to a "buy" rating and raised their target price for the company from $340.00 to $450.00 in a research note on Tuesday. UBS Group upgraded shares of Medpace from a "neutral" rating to a "buy" rating and raised their target price for the company from $282.00 to $452.00 in a research note on Thursday, February 15th. StockNews.com upgraded shares of Medpace from a "hold" rating to a "buy" rating in a research note on Tuesday. Deutsche Bank Aktiengesellschaft began coverage on shares of Medpace in a research note on Monday, March 18th. They issued a "hold" rating and a $395.00 target price for the company. Finally, Robert W. Baird raised their target price on shares of Medpace from $312.00 to $408.00 and gave the company an "outperform" rating in a research note on Wednesday, February 14th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $395.60.

Medpace Trading Up 8.2 %

MEDP stock traded up $30.89 during mid-day trading on Tuesday, hitting $407.15. 808,112 shares of the company were exchanged, compared to its average volume of 249,150. The business has a 50 day simple moving average of $397.68 and a 200-day simple moving average of $323.14. The stock has a market capitalization of $12.61 billion, a PE ratio of 45.85, a price-to-earnings-growth ratio of 1.97 and a beta of 1.38. Medpace Holdings, Inc. has a 1-year low of $187.03 and a 1-year high of $419.42.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its quarterly earnings data on Monday, April 22nd. The company reported $3.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.45 by $0.75. The firm had revenue of $511.00 million during the quarter, compared to the consensus estimate of $512.39 million. Medpace had a net margin of 15.00% and a return on equity of 63.98%. The business's revenue for the quarter was up 17.7% compared to the same quarter last year. During the same period last year, the business posted $2.27 earnings per share. Equities research analysts expect that Medpace Holdings, Inc. will post 10.53 earnings per share for the current year.

Medpace Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.